Pfizer, Moderna Covid-19 vaccines highly effective after first shot in real-world use, US study shows | The Business Standard
Skip to main content
  • Home
  • Economy
    • Aviation
    • Banking
    • Bazaar
    • Budget
    • Industry
    • NBR
    • RMG
    • Corporates
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Features
    • Book Review
    • Brands
    • Earth
    • Explorer
    • Food
    • Habitat
    • In Focus
    • Luxury
    • Mode
    • Panorama
    • Pursuit
    • Wheels
  • Epaper
    • GOVT. Ad
  • More
    • Subscribe
    • Videos
    • TBS Graduates
    • Thoughts
    • Splash
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • COVID-19
    • Long Read
    • Interviews
    • Offbeat
    • Tech
    • Magazine
  • বাংলা
The Business Standard

Wednesday
December 06, 2023

Sign In
Subscribe
  • Home
  • Economy
    • Aviation
    • Banking
    • Bazaar
    • Budget
    • Industry
    • NBR
    • RMG
    • Corporates
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Features
    • Book Review
    • Brands
    • Earth
    • Explorer
    • Food
    • Habitat
    • In Focus
    • Luxury
    • Mode
    • Panorama
    • Pursuit
    • Wheels
  • Epaper
    • GOVT. Ad
  • More
    • Subscribe
    • Videos
    • TBS Graduates
    • Thoughts
    • Splash
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • COVID-19
    • Long Read
    • Interviews
    • Offbeat
    • Tech
    • Magazine
  • বাংলা
WEDNESDAY, DECEMBER 06, 2023
Pfizer, Moderna Covid-19 vaccines highly effective after first shot in real-world use, US study shows

Coronavirus chronicle

Reuters
30 March, 2021, 10:55 am
Last modified: 30 March, 2021, 11:29 am

Related News

  • Bolsonaro home raided, phone seized in Brazil vaccine records probe
  • WHO provides 11 lakh bivalent vaccines to Bangladesh: Minister
  • Incepta Pharma abandons Covid vaccine plan
  • Moderna reports positive results for RSV vaccine
  • Pfizer expects to hike US Covid vaccine price to $110-$130 per dose

Pfizer, Moderna Covid-19 vaccines highly effective after first shot in real-world use, US study shows

The risk of infection fell 90% by two weeks after the second shot, the study of nearly 4,000 US healthcare personnel and first responders found

Reuters
30 March, 2021, 10:55 am
Last modified: 30 March, 2021, 11:29 am
FILE PHOTO: Vials labelled "COVID-19 Coronavirus Vaccine" and a syringe are seen in front of the Pfizer logo in this illustration taken February 9, 2021. REUTERS/Dado Ruvic/Illustration/File Photo
FILE PHOTO: Vials labelled "COVID-19 Coronavirus Vaccine" and a syringe are seen in front of the Pfizer logo in this illustration taken February 9, 2021. REUTERS/Dado Ruvic/Illustration/File Photo

Covid-19 vaccines developed by Pfizer Inc with BioNTech SE and Moderna Inc reduced risk of infection by 80% two weeks or more after the first of two shots, according to data from a real-world US study released on Monday.

The risk of infection fell 90% by two weeks after the second shot, the study of nearly 4,000 US healthcare personnel and first responders found.

The results validate earlier studies that had indicated the vaccines begin to work soon after a first dose, and confirm that they also prevent asymptomatic infections.

The Business Standard Google News Keep updated, follow The Business Standard's Google news channel

Some countries dealing with limited vaccine supplies have pushed back schedules for second doses with the hope of getting some protection to more people. US public health officials, however, continue to recommend two doses be given on the schedule authorized by regulators based on clinical trials.

The study by the US Centers for Disease Control and Prevention (CDC) evaluated the vaccines' ability to protect against infection, including infections that did not cause symptoms. Previous clinical trials by the companies evaluated their vaccine's efficacy in preventing illness from Covid-19, but those studies would have missed asymptomatic infections.

The findings from of the real-world use of these messenger RNA (mRNA) vaccines also confirm the efficacy demonstrated in the large controlled clinical trials conducted before they received emergency use authorizations from the US Food and Drug Administration.

The study looked at the effectiveness of the mRNA vaccines among 3,950 participants in six states over a 13-week period from Dec. 14, 2020 to March 13, 2021. About 74% had at least one shot, and tests were conducted weekly to catch any infections without symptoms.

"The authorized mRNA Covid-19 vaccines provided early, substantial real-world protection against infection for our nation's healthcare personnel, first responders, and other frontline essential workers," CDC Director Rochelle Walensky said in a statement.

FILE PHOTO: Vials with a sticker reading "Covid-19/Coronavirus vaccine/Injection only" and a syringe are seen in front of a displayed Moderna logo in this illustration taken October 31, 2020. REUTERS/Dado Ruvic/Illustration/File Photo
FILE PHOTO: Vials with a sticker reading "Covid-19/Coronavirus vaccine/Injection only" and a syringe are seen in front of a displayed Moderna logo in this illustration taken October 31, 2020. REUTERS/Dado Ruvic/Illustration/File Photo

The new mRNA technology is a synthetic form of a natural chemical messenger being used to instruct cells to make proteins that mirror part of the novel coronavirus. That teaches the immune system to recognize and attack the actual virus.

The CDC study comes weeks after real-world data from Israel suggested that the Pfizer/BioNTech vaccine was 94% effective in preventing asymptomatic infections.

Britain and Canada were among the countries that have allowed extended gaps between doses of up to three or four months. UK authorities said in January that data supported its decision for a 12-week gap between doses.

Pfizer and its German partner have warned that they had no evidence to prove that. In their pivotal trials, there was a three-week gap between Pfizer shots and four weeks for the Moderna vaccine.

The CDC said the study results on Monday provide reassurance that people start to develop protection from the vaccine two weeks after their first dose, although the agency reiterated that the greatest protection was seen among those who had received both recommended doses of the vaccines.

Top News

Pfizer Covid-19 Vaccine / Pfizer-BioNTech coronavirus vaccine / Pfizer-BioNTech vaccine / Pfizer-19 Vaccine / Moderna Covid-19 Vaccine / Moderna Vaccine / Moderna Inc / covid-19 vaccine / Coronavirus Vaccine / US CDC / The Communicable Disease Control (CDC)

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • EC publishes full list of 96 local election observers with 29 new names
    EC publishes full list of 96 local election observers with 29 new names
  • Illustration: TBS
    Bangladesh Bank doubles limit for sending remittances through MFS
  • File photo of Election Commissioner Mohammad Alamgir. Photo: Collected
    Foreigners have not put pressure on Election Commission over polls: EC Alamgir

MOST VIEWED

  • This file photo from December 2019 shows a rider driving his motorcycle through cold wind and fog. A scene not yet visible this year. Photo: Mumit M
    Woe for seasonal crops, vegetables as winter comes late 
  • Caption: Illustration: TBS
    Source tax on land registration cut again
  • File Photo: Reuters
    $1.08 billion could be added to Bangladesh's dwindling forex reserves
  • Photo: Courtesy
    Woman entrepreneur Sangeeta Khan dies at age 62
  • 59 DSE stocks face downgrade to junk category
    59 DSE stocks face downgrade to junk category
  • Dollar pressure rises as short-term foreign debt drops $300m in October
    Dollar pressure rises as short-term foreign debt drops $300m in October

Related News

  • Bolsonaro home raided, phone seized in Brazil vaccine records probe
  • WHO provides 11 lakh bivalent vaccines to Bangladesh: Minister
  • Incepta Pharma abandons Covid vaccine plan
  • Moderna reports positive results for RSV vaccine
  • Pfizer expects to hike US Covid vaccine price to $110-$130 per dose

Features

Photo: Rexy Jason Gomez

A big love for the small wheels

3h | Features
Dhaka’s FDC,  Japan Garden City and Shia Masjid were all part of Gudaraghat once. PHOTOS:  Syed Zakir Hossain

What the remaining Gudaraghats remind us of Dhaka's long-lost water bodies

11h | Panorama
A trove of research underscores the perilous consequences of relying on plastic utensils, a narrative mirrored by the western world's pivot towards sustainable alternatives - ceramic, brass, or clay dinnerware. PHOTO: TBS

While we lose our sustainable traditions, the West pivots in the opposite direction

10h | Panorama
Ghulam Ali

Ghulam Ali: Voice that makes ghazals bloom

1d | Features

More Videos from TBS

What is 'obstructing the field' out?

What is 'obstructing the field' out?

2h | TBS SPORTS
When Farooki is hero

When Farooki is hero

1h | TBS Entertainment
Most Ukrainians are losing interest in going to war

Most Ukrainians are losing interest in going to war

4h | TBS World
Putin to visit UAE and Saudi Arabia

Putin to visit UAE and Saudi Arabia

6h | TBS World
EMAIL US
contact@tbsnews.net
FOLLOW US
WHATSAPP
+880 1847416158
The Business Standard
  • About Us
  • Contact us
  • Sitemap
  • Privacy Policy
  • Comment Policy
Copyright © 2023
The Business Standard All rights reserved
Technical Partner: RSI Lab

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - oped.tbs@gmail.com

For advertisement- sales@tbsnews.net